EUVIMEDEUVIMED entdecken
Crossref

Development of a First-in-Class DNMT1/HDAC Inhibitor with Improved Therapeutic Potential and Potentiated Antitumor Immunity

Yingjie Chang, Huahui Guo, Xue Li, Liangyi Zong, Jiale Wei, Zhihai Li iD, Cheng Luo iD, Xinying Yang, Hao Fang iD, Xiangqian Kong iD, Xuben Hou iD

Journal of Medicinal Chemistry · 26.09.2024 · 67 (18) · 16480-16504

DOI: 10.1021/acs.jmedchem.4c01310 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 12.09.2024. Verfasst von Yingjie Chang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University…. Hauptthemen laut MEDLINE: Histone Deacetylase Inhibitors, DNA (Cytosine-5-)-Methyltransferase 1, Antineoplastic Agents. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 77 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Basic and Applied Basic Research Foundation of Guangdong Province, Taishan Scholar Project of Shandong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epigenetic therapies have emerged as a key paradigm for treating malignancies. In this study, a series of DNMT1/HDAC dual inhibitors were obtained by fusing the key pharmacophores from DNMT1 inhibitors (DNMT1i) and HDAC inhibitors (HDACi). Among them, compound (R)-23a demonstrated significant DNMT1 and HDAC inhibition both in vitro and in cells and largely phenocopied the synergistic effects of combined DNMT1i and HDACi in reactivating epigenetically silenced tumor suppressor genes (TSGs). This translated into a profound tumor growth inhibition (TGI = 98%) of (R)-23a in an MV-4-11 xenograft model, while displaying improved tolerability compared with single agent combination. Moreover, in a syngeneic MC38 mouse colorectal tumor model, (R)-23a outperformed the combinatory treatment in reshaping the tumor immune microenvironment and inducing tumor regression. Collectively, the novel DNMT1/HDAC dual inhibitor (R)-23a effectively reverses the cancer-specific epigenetic abnormalities and holds great potential for further development into cancer therapeutic agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Histone Deacetylase InhibitorsDNA (Cytosine-5-)-Methyltransferase 1Antineoplastic AgentsAnimalsHumansMiceCell Line, TumorHistone DeacetylasesCell ProliferationEpigenesis, GeneticFemale

Substanzen

Histone Deacetylase InhibitorsDNA (Cytosine-5-)-Methyltransferase 1DNMT1 protein, humanAntineoplastic AgentsHistone Deacetylases

Autor:innen und Institutionen

  • Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, 44 Wenhuaxi Road, Jinan 250012, China.
  • State Key Laboratory of Respiratory Disease, China-New Zealand Joint Laboratory on Biomedicine and Health, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangzhou Institutes of Biomedicine…
  • University of Chinese Academy of Sciences (UCAS), 19 Yuquan Road, Beijing 100049, China.
  • School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, China.
  • State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China.

ORCID-Profile: Zhihai Li, Cheng Luo, Hao Fang, Xiangqian Kong, Xuben Hou

Förderung

  • National Key Research and Development Program of China
  • Basic and Applied Basic Research Foundation of Guangdong Province
  • Taishan Scholar Project of Shandong Province
  • Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences
  • Shandong University
  • National Natural Science Foundation of China
  • Lingang Laboratory
  • Pearl River Talents Plan

Zitieren

APA

Chang, Y., Guo, H., Li, X., Zong, L., Wei, J., Li, Z., Luo, C., Yang, X., Fang, H., Kong, X., & Hou, X. (2024). Development of a First-in-Class DNMT1/HDAC Inhibitor with Improved Therapeutic Potential and Potentiated Antitumor Immunity. Journal of Medicinal Chemistry, 67(18), 16480-16504. https://doi.org/10.1021/acs.jmedchem.4c01310

Vancouver

Chang Y, Guo H, Li X, Zong L, Wei J, Li Z, et al. Development of a First-in-Class DNMT1/HDAC Inhibitor with Improved Therapeutic Potential and Potentiated Antitumor Immunity. Journal of Medicinal Chemistry. 2024;67(18):16480-16504. doi:10.1021/acs.jmedchem.4c01310

BibTeX
@article{Chang2024,
  author = {Chang, Yingjie and Guo, Huahui and Li, Xue and Zong, Liangyi and Wei, Jiale and Li, Zhihai and Luo, Cheng and Yang, Xinying and Fang, Hao and Kong, Xiangqian and Hou, Xuben},
  title = {Development of a First-in-Class DNMT1/HDAC Inhibitor with Improved Therapeutic Potential and Potentiated Antitumor Immunity},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  volume = {67},
  number = {18},
  pages = {16480--16504},
  doi = {10.1021/acs.jmedchem.4c01310}
}
Kostenlos starten →